Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "subclinical" pheochromocytoma. Academic Article uri icon

Overview

abstract

  • OBJECTIVE: To assess the risk of pheochromocytoma in patients with borderline-elevated urine or plasma metanephrine levels. DESIGN: Retrospective review. SETTING: University tertiary care center. PATIENTS: Forty-two consecutive patients with adrenal incidentalomas (defined as adrenal tumors identified during routine imaging for another condition) who were treated at the UCSF (University of California, San Francisco) Medical Center between January 1, 1995, and July 31, 2005. Patients with genetic syndromes were excluded. INTERVENTION: Laparoscopic adrenalectomy for adrenal incidentaloma based on size criteria and preoperative hormonal test results. MAIN OUTCOMES MEASURES: Urine or plasma metanephrine and catecholamine levels, tumor size, and presence of pheochromocytoma. RESULTS: Of 42 patients, 14 (33%) had a pheochromocytoma (11 of whom had clear-cut elevations in urine or plasma metanephrine levels defined as greater than 2 times the upper limit of normal) and 28 did not. Ten of the 42 patients (24%) had borderline elevations in urine or plasma metanephrine levels (defined as 1-2 times the upper limit of normal), 3 of whom had a pheochromocytoma (30%). Of patients with borderline elevations, mean +/- SD tumor size was 5.4 +/- 3.1 and 4.8 +/- 1.9 cm for patients with and without pheochromocytoma, respectively (P = .37). In these 10 patients, no clinical factors (age, sex, hypertension, presence of symptoms, number of antihypertensive medications, preoperative hemodynamics, or size of tumor on computed tomographic scan) allowed differentiation between those with and without pheochromocytoma. CONCLUSIONS: Thirty percent of patients with adrenal incidentaloma and borderline-elevated urine or plasma metanephrine levels had a pheochromocytoma. Clinical factors cannot distinguish between those with and without pheochromocytoma. In this group of patients, we advocate either routine alpha-blockade preoperatively or further diagnostic tests to better characterize the tumor.

publication date

  • September 1, 2007

Research

keywords

  • Adrenal Gland Neoplasms
  • Metanephrine
  • Pheochromocytoma

Identity

Scopus Document Identifier

  • 34548803141

Digital Object Identifier (DOI)

  • 10.1001/archsurg.142.9.870

PubMed ID

  • 17875842

Additional Document Info

volume

  • 142

issue

  • 9